The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Regulus Therapeutics will be acquired by Novartis AG for $7 per share in cash. Click here for more information on RGLS ...

The four anti-CD20 drugs used in the U.S. to treat relapsing MS -- ocrelizumab, ofatumumab, and ublituximab (Briumvi; ...

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...

Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

At the heart of the acquisition is Regulus’ farabursen, an miRNA-targeting oligonucleotide in early-stage development for ...

Despite patent expirations, Novartis' strong cash flow, ongoing buyback, and low-risk profile support our continued buy ...

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making ...

Novartis is buying Regulus for $800 million, picking up the biotech's experimental kidney drug that's based off a ...

Novartis is set to buy U.S. biotech Regulus Therapeutics for up to $1.7 billion in a move to boost its renal-disease pipeline. The Swiss pharma giant said Wednesday that it would pay Regulus ...